Quick Answer
Autolus Therapeutics plc reported Revenue (ASC 606) of $75.39 million for fiscal year 2025.
Autolus Therapeutics plc Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $75.39M | +644.9% |
| 2024 | $10.12M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.19M | — | +1.3% |
| June 30, 2025 | $20.92M | — | — |
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | — | — |
- Autolus Therapeutics plc showed an increase of +644.9% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2024–2025 period, Autolus Therapeutics plc’s revenue (asc 606) has grown by 644.9% (from $10.12 million to $75.39 million).
- The most recent figure is from Autolus Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: